Medicure ups stake in Apicore

11 July 2017
mergers-acquisitions-big

Medicure (TSXV: MPH), a Canadian specialty pharma focused on the development and commercialization of therapeutics for the US hospital market, has exercised an option to snap up additional interests in Apicore, the New Jersey-based API developer and manufacturer.

The option exercise allows for the acquisition of all of the shares held by Apicore’s founding shareholders - representing approximately 32% of the fully diluted ownership - for $24.5 million.

This acquisition brings Medicure's ownership in Apicore to approximately 98%, or 94% on a fully-diluted basis.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Generics